Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene

Current therapies for localized prostate cancer include radical prostatectomy, local radiation therapy, and cryoablation and are associated with a high rate of cure and acceptable morbidity. However, for men who have failed primary curative attempts or have metastatic disease, no effective therapy a...

Full description

Saved in:
Bibliographic Details
Published in:World journal of urology 2000-04, Vol.18 (2), p.125-129
Main Authors: Shalev, M, Miles, B J, Thompson, T C, Ayala, G, Butler, E B, Aguilar-Cordova, E, Kadmon, D
Format: Article
Language:English
Subjects:
Adenoviridae - genetics
Adenoviridae - growth & development
Adenovirus
Adenoviruses
Cancer therapies
Clinical Trials, Phase I as Topic
Gene Expression Regulation, Viral
Genetic Therapy - methods
Genetic Vectors
Herpesvirus
Humans
Male
Prostate cancer
Prostatic Neoplasms - therapy
Simplexvirus - enzymology
Simplexvirus - genetics
Suicides & suicide attempts
Thymidine Kinase - genetics
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current therapies for localized prostate cancer include radical prostatectomy, local radiation therapy, and cryoablation and are associated with a high rate of cure and acceptable morbidity. However, for men who have failed primary curative attempts or have metastatic disease, no effective therapy associated with acceptable morbidity exists. "Suicide" gene therapy delivered alone or in combination with other forms of treatment could potentially provide simultaneous efficacy against localized and systemic disease via the generation of cytotoxic activity and/or systemic immunity to the cancer. In this article we discuss our preclinical and clinical experience with a herpes-simplex-virus thymidine kinase/ganciclovir gene-therapy protocol for prostate cancer.
ISSN:0724-4983
1433-8726
DOI:10.1007/s003450050184